Clinical and Pharmaceutical Studies
Sponsor – Eli Lilly & Co
Title – A Randomized, Double-Blinded Study with an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Pediatric Patients with Type 2 Diabetes Mellitus (AWARD-PEDS) H9X-MC-GBG
Description
Clinical trial of a novel therapy for children with Diabetes Type2.
Sponsor – Lurie Children’s (Prime sponsor: NIH)
Title – Effectiveness of an e-health intervention
Description
UIC is a site for this trial, led by Lurie Children’s Hospital, which aims to determine effectiveness of the use of technology for care support in minority children with diabetes.
Sponsor – North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS)
https://naprtcs.org/
Title – Measurement of Negative Inspiratory Flow (NIF) in Children Aged 4-8 Years During an Acute Asthma Exacerbation to Predict Effectiveness of Dry Powder Inhaler – A Pilot Study
Description – There are several types of Dry Powder Inhaler (DPI) devices currently on the market used for delivering glucocorticoids, beta-agonists, or combination medication (i.e. diskus, twisthaler/turbuhaler, respiClick). Each type of DPI has a different intrinsic resistance to airflow that determines how much inspiratory flow needs to be created in the device to release the correct amount of drug. Children who cannot achieve the recommended/optimal negative inspiratory flow (NIF) through their prescribed DPI may not obtain the maximum benefit from their medication. In this study, we will evaluate the use of DPI use in children during an acute asthma exacerbation, when NIF is inherently reduced. We hypothesize that the use of DPIs in children aged 4<8 during an asthma exacerbation has limited benefit, as children are unable to generate the needed NIF.
Sponsor – IL Dept of Public Health (IDPH)
Title – Regionalized Care in the Treatment of Biochemical Genetic Diseases Detected from State of IL Newborn
Sponsor – London North West Healthcare NHS Trust (UK)
Title –Marie Sklodowska-Curie Actions – Research and Innovation Staff Exchange
Description
The role of Dr. Hsu and UIC Sickle Cell Center role will be specifically to “train the trainers” on sickle cell disease Community Health Workers and Implementation Science, including.
(1) In short courses and workshops, Dr. Lewis Hsu will train ARISE personnel in the principles of Community Health Workers (CHW) and Implementation Science, and practical application to sickle cell disease. The “train the trainer” approach will equip the ARISE personnel to identify local stakeholders in sickle cell, align the goals of these multiple stakeholder groups when introducing new programs, assess their readiness for change, and empower the stakeholders in continuous evaluation of program quality.
(2) ARISE exchange personnel may apply for courses at UIC, which has College of Medicine, College of Nursing, College of Pharmacy, College of Applied Health Sciences, School of Public Health, College of Business Administration, College of Education, College of Dentistry, College of Engineering, College of Urban Planning and Public Affairs, College of Social Work, College of Liberal Arts and Sciences.
(3) Regular check-in with the African and European faculty on program outcomes and sustainability. They will encourage publication of these Implementation Science experiences, which will facilitate further development of sickle cell programs in sub-Saharan Africa.
Funder – The University of Alabama at Birmingham (Prime sponsor: NIH)
Title – DISPLACE
Abstract: DISPLACE is a national, 28-site study, looking at what keeps some children from getting transcranial Doppler exams. Strokes are a common concern for people with sickle cell disease. Sickle cells are misshaped red blood cells that don’t flow easily in the body. They can clump up in brain arteries, damaging the walls of blood vessels and leading to strokes. A transcranial Doppler, or TCD, measures how quickly blood is flowing through vessels in the brain. If we do a TCD and it’s abnormal, you can start transfusion therapy and prevent stroke. Why doesn’t every child with sickle disease get transcranial Doppler screening as often as needed? That’s what the study will find out.
Sponsor – Lurie (Ann & Robert H) Children’s Hospital of Chicago (Prime Sponsor: NIH)
Title = The Pro-Inflammatory Effects of Acute Exercise in Children with Sickle Cell Anemia
Description – UIC is participating in a multi-site study hosted at Lurie Children’s Hospital of Chicago examining the pro-inflammatory effects of moderate to vigorous physical activity and exercise in children with sickle cell anemia (SCA). The ultimate goal of the study to develop evidence-based guidelines for exercise and physical activity as a transformative strategy to maintain physical functioning and health in children with SCA.
Funder – Children’s Hospital of Philadelphia (Prime sponsor: NIH)
Title – Chronic Kidney Disease in Children
Abstract: Chronic kidney disease (CKD) is a life-long condition that often results in substantial morbidity and premature death due to complications from a progressive decrease in kidney function. The early detection of, and initiation of therapy for, CKD is key to delaying or preventing progression to end-stage renal disease (ESRD). The CKiD (Chronic Kidney Disease in Children) study is a prospective cohort study of children with CKD that investigates risk factors and outcomes of the disease.
Funder – IL Dept of Public Health (IDPH)
Title – University of Illinois Administrative Perinatal Center
Funder – Gerber Foundation
Title – Optimizing Intravenous Protein Nutrition in Premature Infants Using Urine Metabolomics
PI Pillers, De-Ann - Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia
Funder – Duke Clinical Research Institute (Prime Sponsor: NIH)
Title – Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia
Funder – Children’s Oncology Group/Children’s Hospital of Philadelphia (Prime sponsor: NIH), St Baldrick’s Foundation, Circle of Service Foundation
Title – Many cancer studies
Title – A Retrospective Analysis of Acute Kidney Injury in VLBW Infants
Funder – Univ of WA (Primary sponsor: NIH NINDS)
Title – Preterm Epo Neuroprotection Trial (PENUT Trial) CCC
Description
The aim of this NINDS funded trial is to assess whether high dose Epo will improve survival without neurodevelopmental impairment (NDI) in infants born between 24 and 28 weeks of gestation (term is 40 weeks). 940 infants will be enrolled at 16 centers across the U.S. Subjects will be assessed at 2 years of age to see whether Epo treatment will improve neurodevelopmental outcomes.
Title – Wearable sensors and video recording for children (birth to 24 months) to monitor motor development
Title – Blood Pressure Trends in Very Low-Birth Weight Infants and Contributors of Neonatal Hypertension